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Doctors prescribe inefficiently. Many conditions, such as
hypertension, are inadequately treated whereas others,
such as depression, are overtreated. Bearing in mind the
plethora of guidelines now available on virtually every
sector of medicine, this seems inexcusable. Whether due
to ignorance, indolence, or incredulity, many physicians
are not implementing the recommendations of 'experts'.
Conscientious clinicians may think that the advice availa-
ble from the 'experts' does not apply to the patients they
see and will want to assess the evidence for themselves, so
that their practice will provide the best management for
their patients. It is for such people that this book has been
written. The writing is excellent and it is embellished by
amusing cartoons and witty one-line quotations. The
authors have tried, but not completely succeeded, in
avoiding statistics. Their extensive personal experience has
enabled them to give good examples to illustrate their
points, although they also quote widely from the world
literature.
They start by emphasizing the importance of evaluating
the balance between benefit and harm. Unfortunately, all
too often, papers and presentations, as well as pharma-
ceutical companies, often highlight the benefits of new
treatments while saying little about the adverse effects.
The value of randomized controlled trials (RCTs) as the
bedrock of evidence-based medicine is unquestionable,
but the shortcomings are often ignored-especially by
'experts'. The authors discuss both the strengths and weak-
nesses of randomized RCTs. The chapter on weaknesses is
largely concerned with the inability of RCTs, because of
their limited size, to recognize rare side effects. Although
referred to later in the book, the unrepresentative nature
of those recruited into trials is given insufficient attention.
This is a major reason why practising physicians are often
sceptical about the results of trials.
Having stressed that RCTs 'rank highly in terms of reliabil-
ity for evaluating treatments,' one may question the
authors' claim that 'at the top of the ranking are meta-
analyses of clinical trials'. In fact, as experience has shown,
large individual trials may provide more convincing evi-
dence than a meta-analysis.
In later chapters, they consider such important topics as
the doubtful value of surrogate endpoints and biochemi-
cal markers, and they also discuss whether active controls
can be relied upon and whether all drugs in a class are
interchangeable. Much attention is paid to the measure-
ment of adverse drug reactions but here, as elsewhere, dis-
cussion is focused on practices in the United States,
whereas these issues are often better tackled in other coun-
tries (where many of their readers will be located).
Overall, this is an excellent book that can be strongly rec-
ommended to the target audience which is, as the authors
state, ''clinicians and others in the health care field as well
as employees in companies manufacturing drugs, devices
and other medical products'.
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